Pharmacy funding at a glance
| Product | How much | Best for |
|---|---|---|
| SBA 7(a) loan | Up to $5,000,000; up to 10 years (25 with real estate) | Buying a pharmacy — the dominant vehicle for acquisitions, including goodwill and inventory |
| SBA 504 loan | Up to $5,000,000 debenture ($5,500,000 for small manufacturers and certain energy projects); 10, 20, or 25 years | Owner-occupied real estate and long-life equipment — cannot fund working capital, inventory, or goodwill |
| Combined SBA | Up to $10,000,000 total since July 4, 2026 | Pairing a 7(a) acquisition loan with a 504 building or equipment loan |
| A/R line of credit | 75 to 85 percent of eligible receivables advanced | Bridging the wholesaler-to-PBM payment gap |
| Inventory financing | 50 to 70 percent of eligible inventory value as revolving credit | Drug stock — the largest single expense, and the asset the lender can underwrite |
| Wholesaler financing (McKesson RxOwnership) | Promissory notes, typically 3 to 7 years, maximum 7 years; plus extended payment terms ("dating") | Opening inventory and ownership transfers for qualified buyers |
| Merchant cash advance | Sized to revenue; funding in as little as 24 to 72 hours | A short-term payroll or inventory gap — the most expensive money on this page, and the only product with no pharmacy-specific rates published |
The short version: an independent pharmacy is a $5.4 million-a-year business with a 21 percent gross margin and a cash-flow hole built into its model — the wholesaler wants paying in 14 to 30 days, the pharmacy benefit manager pays in 30 to 60, and the final reimbursement number can take 4 to 12 months to settle. The funding that fits a pharmacy is the funding that bridges that gap, and the cheapest route to owning one is still the SBA 7(a) loan, now combinable with a 504 to $10 million.
The independent pharmacy in 2026
There are 18,988 independent community pharmacies in the United States in 2026, essentially unchanged from 18,960 in 2025, representing about 37 percent of all retail pharmacies. Together they are a $103 billion marketplace, with over 96 percent of sales coming from the prescription department. The average independent dispensed 65,795 prescriptions in 2025 — about 211 a day — at an average charge of $79.20, on average annual sales of $5,411,000 per location in 2024, up from $4,997,000 in 2023. Gross margin was 20.9 percent in 2025, up from 18.2 percent in 2024, a 10-year low. About 19,000 independents employ more than 230,000 people, and about a third are in communities of fewer than 10,000 people. Eighty-one percent of prescriptions are filled with generics; 91 percent of independents provided flu immunizations in 2025, 81 percent offered medication therapy management, and 55 percent deliver long-term care services.
The pressure side is real. Between 2022 and 2024, 7,240 US community pharmacies closed against 4,178 opened — a net loss of 3,062. Independents and franchises lost a net 382 (3,839 closed, 3,457 opened) while chains lost 2,680. In 2024 alone, 1,570 independent pharmacies closed, and closed pharmacies had operated an average of 18.7 years — independents 15 years and 8.8 months. A pharmacy that survives is not a lucky one; it is one whose reimbursement math and cash flow are managed tightly, and that is exactly what a lender underwrites.
The cash-flow gap that drives the borrowing
Pharmacy funding is different from most small-business funding because the timing gap is structural, not seasonal. Wholesalers typically demand payment in 14 to 30 days, on weekly or bi-weekly settlement, while pharmacy benefit manager reimbursement lags 30 to 60 days, with direct and indirect remuneration reconciliation adding months. A $10 profit can turn into a net loss months later once the clawbacks hit.
Direct and indirect remuneration fees — retroactive price concessions PBMs assessed against pharmacies weeks or months after dispensing, based on opaque performance metrics like adherence, generic dispensing rate, and medication therapy management completion — grew 107,400 percent from 2010 to 2020, according to CMS data cited by the National Community Pharmacists Association. In an NCPA survey, 84 percent of independent owners said they never know their final reimbursement at point of sale, and 77 percent said it takes 4 to 12 months before the final number is known. A CMS final rule effective January 1, 2024, moved those concessions to the point of sale, ending retroactive clawbacks for Medicare Part D — but it did not eliminate the fees, and pharmacies reported that PBMs responded by lowering baseline reimbursement rates, with up-front Part D reimbursement in 2024 falling to its lowest level since 2016. Pharmacies receive insurance reimbursement below acquisition cost for about 15 percent of generic medicines, and even for brand-name drugs reimbursement is often equal to or less than acquisition cost. The Big Three PBMs — CVS Caremark, Express Scripts, and OptumRx — control 80 to 90 percent of the prescription market.
That gap is the funding need. A pharmacy does not borrow because it is unprofitable — at a 20.9 percent gross margin on $5.4 million in sales, the average independent is profitable. It borrows because it pays for the drugs this month and gets paid for them next quarter, and the final number is not known for months after that.
What pharmacy loans pay for
Inventory and drug stock — the largest single expense. Initial inventory for a community pharmacy typically runs $200,000 to $350,000. A store filling 200 scripts a day typically carries $80,000 to $150,000 in inventory; a 350-script-a-day store $150,000 to $250,000. A single specialty prescription — oncology, autoimmune, rare disease, HIV — can cost $5,000 to $30,000 or more in inventory.
Opening a pharmacy from scratch. Total startup runs $250,000 to $750,000: inventory $100,000 to $200,000, fixtures and equipment $50,000 to $150,000, lease build-out $40,000 to $120,000, plus about six months of operating reserves. Other estimates put startup at $400,000 to $1.5 million or more depending on location and size. New stores are typically cash-negative for the first six months due to the reimbursement lag, with break-even around 15 to 24 months after opening.
Buying an existing pharmacy. Typically $300,000 to $1.5 million. Pharmacies sell for 2 to 4 times annual net profit, or 2.5 to 3 times EBITDA for goodwill plus inventory at cost — a profitable independent selling for $1.8 million is not unusual in 2026. Inventory is priced separately, at cost. Compounding pharmacies carry 40 to 60 percent gross margins on compounded preparations against low single-digit to mid-single-digit margins on traditional dispensing, which is a key reason they command higher valuations; a compounding cleanroom buildout runs $150,000 to $600,000 or more.
Payroll and working capital. Bridging the wholesaler-to-PBM gap is the recurring need, not a one-time project. Expansion and equipment. A second location, automated dispensing systems, fixtures, and delivery vehicles.
SBA 7(a): the acquisition vehicle
The 7(a) loan is the dominant vehicle for pharmacy acquisitions, and the numbers explain why. The maximum single loan is $5,000,000, with the SBA guaranteeing 85 percent up to $150,000 and 75 percent above that, and maximum SBA guaranty exposure of $3.75 million per borrower including affiliates. Since July 4, 2026, under SBA Policy Notice 5000-879058, a borrower can combine 7(a) and 504 programs for up to $10,000,000 in total SBA-backed financing — up to $5 million in 7(a) plus up to $5 million in 504 per borrower, with per-program maximums unchanged.
The rate caps are ceilings, not quotes: for variable-rate 7(a) loans, prime plus 6.5 percent on loans up to $50,000, plus 6.0 percent from $50,001 to $250,000, plus 4.5 percent from $250,001 to $350,000, and plus 3.0 percent above $350,000. With prime at 7.00 percent in October 2026, the caps are 13.50, 13.00, 11.50, and 10.00 percent. Third-party estimates put rates actually quoted for pharmacy deals at 10.5 to 13.5 percent APR in one listing and 8.75 to 10.5 percent all-in in another — present those as ranges from those sources, not as guaranteed rates.
The typical acquisition deal structure is 10 percent buyer equity, an SBA lender covering 80 to 85 percent, and the seller often carrying 5 to 10 percent as a standby note subordinated for 24 months. One published example: a $1.5 million loan at 9.5 percent over 10 years runs about $19,400 a month in debt service, and lenders typically require a minimum 1.25 times debt-service coverage — deal sizing works backward from EBITDA, so about $280,000 of EBITDA supports roughly a $1.44 million loan at mid-2026 rates. The pharmacy-specialty SBA banks most often named are Live Oak Bank, with a dedicated pharmacy and healthcare team, and First Financial Bank; SmartBiz is named for smaller 7(a) loans under $350,000. Terms run 10 years for acquisitions and up to 25 years when real estate is involved.
SBA 504: for the building, not the business
The 504 loan is the fixed-rate, long-term route for major fixed assets: owner-occupied real estate and long-life equipment with a 10-year useful life minimum, on terms of 10, 20, or 25 years, with down payments as low as 10 percent and a job creation and retention requirement. The maximum debenture is $5,000,000 generally, or $5.5 million for small manufacturers and certain energy projects. It cannot fund working capital or inventory — and it cannot finance goodwill, so it is not the right structure for a pharmacy acquisition. Use the 7(a) for the acquisition and the 504 for the building it sits in.
A/R lines, inventory financing, and the advance
The products that match the reimbursement gap are the revolving ones. An accounts-receivable line of credit finances pending PBM and payor receivables, advancing 75 to 85 percent of eligible invoices while the reimbursement cycle plays out — those are one commercial lender's published ranges, not an industry standard. Inventory financing treats on-hand drug inventory as a borrowing-base asset, unlocking 50 to 70 percent of eligible inventory value as revolving credit, on the same caveat. No pharmacy-specific business line-of-credit rate was found from a citable source, so do not plan on a rate range until you have a quote.
A merchant cash advance is the fast, expensive alternative: a purchase of a portion of future receivables, repaid daily or weekly from revenue. No citable source gives pharmacy-specific MCA factor rates, holdback percentages, or typical advance sizes — the product exists for pharmacies, but every specific number is unpublished, so the guide describes the mechanics only in general terms. A $50,000 advance at a 1.30 factor, for illustration, repays $65,000 in total — $15,000 of cost — and the cost does not fall if you repay early unless the agreement says so. Equipment financing for compounding equipment and automated dispensing systems is cited at 6 to 16 percent by one third-party listing — present that as a third-party estimate, not a verified market rate.
Wholesaler financing: McKesson RxOwnership — and what was not verified
McKesson's RxOwnership program is the pharmacy-specific funding channel with the longest track record: no fee, no contract, it has helped more than 9,600 independent pharmacists since 2008, supported more than 5,000 startup pharmacies and more than 4,300 ownership transfers, and provided design services to more than 1,000 pharmacies. For qualified buyers, RxOwnership helps explore short- and long-term financing directly through McKesson: long-term financing typically takes the form of a promissory note with equal amortization, typically 3 to 7 years with a maximum of 7 years, and short-term financing under one year takes the form of dating — extended payment terms — and short-term notes, typically used only for the opening inventory order. Wholesaler financing via dating is listed as one of the most common financing options for pharmacy sales, alongside traditional lenders, SBA, seller carry-back, and family loans. McKesson's valuation tool applies a 2.5 times EBITDA multiple plus inventory; the NCPA cites an average of 3 times EBITDA for goodwill plus inventory.
One honest note: two other big wholesalers are often named in pharmacy funding lists, and we could not verify direct lending products from either. Cardinal Health sponsors the NCPA Digest and offers pharmacy business solutions, but no citable source confirms it offers direct financing or loans to independent pharmacies. Cencora, formerly AmerisourceBergen, offers financial guidance and financing strategies plus the Good Neighbor Pharmacy franchise network, but no citable source confirms specific loan products, rates, or extended payment terms offered directly to US independent pharmacies. Do not count on either as a lender until you have a term sheet from them. Seller financing is the other common channel: the seller acts as lender for part of the sale price, often 5 to 10 percent as a standby note.
What lenders look for in a pharmacy file
Prescription volume and trend. Lenders underwrite the prescription file — volume, trend, and transferability of the patient base. A declining-script store is discounted heavily; a 200-script-a-day store is a common reference size.
Payer mix. The Medicaid, commercial, and Medicare Part D mix matters — Part D carries the highest direct and indirect remuneration exposure, and lenders model lowest-common-denominator reimbursement scenarios.
Cash flow and coverage. Lenders typically require a minimum 1.25 times debt-service coverage on acquisition loans, and deal sizing works backward from EBITDA. New stores face 15 to 24 months to break even and are cash-negative early, which makes them harder to finance conventionally.
Clean financials and the DEA clock. Clean, tax-return-matching financials are critical to approval. In an acquisition, DEA registration timing is deal-critical: the new entity needs its own DEA registration, applications take 45 to 90 days, and the seller's registration terminates at close. Inventory, prescription files, equipment, and real estate are the tangible assets lenders underwrite; goodwill-heavy deals rely on cash flow plus a personal guarantee.
One thing not to plan on: no universal credit-score, revenue, or time-in-business minimum for pharmacy loans is published. A single lender's figure — for example, a 680 credit score cited for one specialty bank — is that lender's published figure, not an SBA requirement.
A $1.5 million pharmacy acquisition, priced out
Take the published example: a $1.5 million SBA 7(a) acquisition loan at 9.5 percent over 10 years runs about $19,400 a month in debt service. At the typical 1.25 times coverage requirement, the pharmacy needs about $24,250 a month — about $291,000 a year — in cash flow available for debt service, which is why deal sizing works backward from EBITDA: about $280,000 of EBITDA supports roughly a $1.44 million loan at mid-2026 rates. The buyer puts in 10 percent equity — about $150,000 on a $1.5 million deal — the SBA lender covers 80 to 85 percent, and the seller often carries 5 to 10 percent as a standby note subordinated for 24 months. Inventory is priced separately, at cost, on top of the goodwill price. And the working capital is not an afterthought: a 200-script-a-day store carries $80,000 to $150,000 in inventory, the wholesaler wants paying in 14 to 30 days, and the PBM pays in 30 to 60 — so the acquisition loan is only half the financing. The other half is the revolving line that bridges the gap, sized at 75 to 85 percent of eligible receivables or 50 to 70 percent of eligible inventory value.
Five checks before you sign any pharmacy offer
First, the total dollars repaid on your actual amount and term — rate applied to your loan, or factor times amount on an advance, plus every fee. Second, whether the product fits the use: a 504 cannot fund working capital, inventory, or goodwill, and an advance is the wrong tool for a 10-year acquisition. Third, the payment as a share of your slowest month's reimbursement — the PBM cycle, not the sales month, is the cash clock. Fourth, the DEA registration timeline in an acquisition: 45 to 90 days for the new entity, and the seller's registration terminates at close. Fifth, the wholesaler terms in writing — payment window, dating on the opening order, and whether the financing is a promissory note with a stated term. If any of the five is missing, the quote is not comparable.
Frequently asked questions
How much does it cost to buy an independent pharmacy?
Typically $300,000 to $1.5 million. Pharmacies sell for 2 to 4 times annual net profit, or 2.5 to 3 times EBITDA for goodwill plus inventory at cost — a profitable independent selling for $1.8 million is not unusual in 2026. Inventory is priced separately, at cost. The typical structure is 10 percent buyer equity, an SBA lender covering 80 to 85 percent, and the seller often carrying 5 to 10 percent as a standby note.
Can I get an SBA loan to buy a pharmacy?
Yes — the SBA 7(a) loan is the dominant vehicle for pharmacy acquisitions, up to $5 million, with terms of 10 years for acquisitions and up to 25 years when real estate is involved. Since July 4, 2026, a borrower can combine 7(a) and 504 programs for up to $10 million in total SBA-backed financing. The 504 cannot fund goodwill, working capital, or inventory, so it is the wrong tool for the acquisition itself. Lenders typically require a minimum 1.25 times debt-service coverage.
What is the biggest funding problem for independent pharmacies?
The reimbursement timing gap. Wholesalers typically demand payment in 14 to 30 days while PBM reimbursement lags 30 to 60 days, with direct and indirect remuneration reconciliation adding months — and 84 percent of independent owners say they never know their final reimbursement at point of sale. Pharmacies receive reimbursement below acquisition cost for about 15 percent of generic medicines. The funding that fits is the funding that bridges the gap: an A/R line advancing 75 to 85 percent of eligible receivables, or inventory financing at 50 to 70 percent of eligible inventory value.
Does McKesson finance pharmacy purchases?
McKesson's RxOwnership program helps qualified buyers explore short- and long-term financing directly through McKesson — long-term financing typically as a promissory note with equal amortization, typically 3 to 7 years with a maximum of 7 years, and short-term financing as extended payment terms, or dating, typically used only for the opening inventory order. The program has helped more than 9,600 independent pharmacists since 2008. The other two big wholesalers, Cardinal Health and Cencora, could not be verified as direct lenders — do not count on them as financing sources without a term sheet.
How long does it take to buy a pharmacy?
The financing clock is the SBA clock — weeks, not days — and the deal-critical constraint is the DEA registration: the new entity needs its own registration, applications take 45 to 90 days, and the seller's registration terminates at close. New stores are typically cash-negative for the first six months due to the reimbursement lag, with break-even around 15 to 24 months after opening.
What do lenders look at first in a pharmacy file?
Prescription volume and trend — the average independent dispensed 65,795 scripts in 2025 — then payer mix, with Medicare Part D carrying the highest remuneration exposure, then cash flow against the 1.25 times debt-service coverage requirement, then clean financials that match the tax returns. A declining-script store is discounted heavily, whatever the top line says.
Bottom line
An independent pharmacy is a $5.4 million-a-year business with a 21 percent gross margin and a payment cycle that runs 30 to 90 days behind its bills — and the funding that fits is the funding that bridges that gap. The SBA 7(a) loan is the acquisition vehicle, up to $5 million and combinable with a 504 to $10 million since July 2026, on a typical structure of 10 percent equity, 80 to 85 percent lender, and a seller note. The working capital rides on an A/R line at 75 to 85 percent of eligible receivables or inventory financing at 50 to 70 percent of eligible inventory value, and McKesson's RxOwnership is the pharmacy-specific channel for qualified buyers. Get the total repayment in dollars, in writing, before you sign — and check it against your slowest reimbursement month, not your best sales month.
The best offer is the one you compare
Get a no-obligation quote from our #1-ranked lender, Coast to Coast Fast Funding — $5K to $5M, MCA and revenue-based products that fund in 24–72 hours with soft-pull-only applications. We shop 75+ lenders so you can compare the true cost of every offer side by side.Apply Now →Soft credit check · 60-second pre-qualification · (352) 809-3201
